UEU-co logo

MD Consult: Books: Goldman: Cecil Medicine: REFERENCES

Goldman: Cecil Medicine, 23rd ed.

Copyright © 2007 Saunders, An Imprint of Elsevier


1. Jackson RD, LaCroix AZ, et al: Calcium plus vitamin D supplementation and the risk of fractures.  N Engl J Med  2006; 354:669-683.

2. Chapuy MC, Arlot ME, Duboeuf F, et al: Vitamin D3 and calcium to prevent hip fractures in the elderly woman.  N Engl J Med  1992; 327:1637-1642.

3. Trivedi DP, Doll R, Khaw KT: Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: Randomised double blind controlled trial.  BMJ  2003; 326:469.

4. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE: Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older.  N Engl J Med  1997; 337:670-676.

5. Grant AM, Avenell A, Campbell MKRECORD Trial Group, et al: Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): A randomised placebo-controlled trial.  Lancet  2005; 365:1621-1628.

6. Writing Group for the PEPI: Effects of hormone therapy on bone mineral density: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.  JAMA  1996; 276:1389-1396.

7. Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial.  JAMA  2002; 288:321-333.

8. Cummings S, Eckert S, Krueger K, et al: The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial.  JAMA  1999; 281:2189-2197.

9. Ettinger B, Black D, Mitlak B, et al: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene.  JAMA  1999; 282:637-645.

10. McClung MR, Geusens P, Miller PD, et al: Effect of risedronate on the risk of hip fracture in elderly women: Hip Intervention Program Study Group.  N Engl J Med  2001; 344:333-340.

11. Black D, Cummings S, Karpf D, et al: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group.  Lancet  1996; 348:1535-1541.

12. Chesnut IC, Skag A, Christiansen C, et al: Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.  J Bone Miner Res  2004; 19:1241-1249.

13. Chesnut 3rd CH, Silverman S, Andriano K, et al: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. PROOF Study Group.  Am J Med  2000; 109:267-276.

14. Meunier PJ, Roux C, Seeman E, et al: The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.  N Engl J Med  2004; 350:459-468.

15. Neer RM, Arnaud CD, Zanchetta JR, et al: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.  N Engl J Med  2001; 344:1434-1441.

16. Greenspan SL, Bone HG, Ettinger MP, et al: Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: A randomized trial.  Ann Intern Med  2007; 146:326-339.

17. de Nijs RNJ, Jacobs JWG, Lems WF, et al: Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.  N Engl J Med  2006; 355:675-684.

18. Orwoll ES, Ettinger M, Weiss S, et al: Alendronate for the treatment of osteoporosis in men.  N Engl J Med  2000; 343:604-610.

Email to Colleague Print Version

Copyright © 2007 Elsevier Inc. All rights reserved. –

Leave a Reply

Time limit is exhausted. Please reload the CAPTCHA.


apply_now Pepperstone Group Limited